Acceleron Pharma Inc. (XLRN) and Dermira Inc. (NASDAQ:DERM) Comparison side by side

Both Acceleron Pharma Inc. (NASDAQ:XLRN) and Dermira Inc. (NASDAQ:DERM) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acceleron Pharma Inc. 43 162.54 N/A -2.59 0.00
Dermira Inc. 9 10.98 N/A -5.34 0.00

Demonstrates Acceleron Pharma Inc. and Dermira Inc. earnings per share (EPS), top-line revenue and valuation.


Table 2 has Acceleron Pharma Inc. and Dermira Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Acceleron Pharma Inc. 0.00% -35.9% -33.4%
Dermira Inc. 0.00% -391.8% -53.3%

Risk & Volatility

A beta of 1.32 shows that Acceleron Pharma Inc. is 32.00% more volatile than S&P 500. Competitively, Dermira Inc.’s beta is 1.34 which is 34.00% more volatile than S&P 500.


The Current Ratio of Acceleron Pharma Inc. is 19.3 while its Quick Ratio stands at 19.3. The Current Ratio of rival Dermira Inc. is 7.1 and its Quick Ratio is has 6.9. Acceleron Pharma Inc. is better equipped to clear short and long-term obligations than Dermira Inc.

Analyst Ratings

In next table is given Acceleron Pharma Inc. and Dermira Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Acceleron Pharma Inc. 0 2 2 2.50
Dermira Inc. 0 2 6 2.75

Acceleron Pharma Inc.’s average target price is $61, while its potential upside is 46.04%. Meanwhile, Dermira Inc.’s average target price is $18.88, while its potential upside is 107.47%. The results from earlier shows that analysts belief suggest that Dermira Inc. seems more appealing than Acceleron Pharma Inc.

Institutional and Insider Ownership

The shares of both Acceleron Pharma Inc. and Dermira Inc. are owned by institutional investors at 86.1% and 78.9% respectively. Insiders owned 13.9% of Acceleron Pharma Inc. shares. Competitively, insiders own roughly 0.3% of Dermira Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Acceleron Pharma Inc. 2.61% -0.92% -0.66% -23.28% 18.82% -3.31%
Dermira Inc. -7.95% -10.27% 42.4% -2.37% -11.27% 43.39%

For the past year Acceleron Pharma Inc. had bearish trend while Dermira Inc. had bullish trend.


On 6 of the 9 factors Acceleron Pharma Inc. beats Dermira Inc.

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. Its therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. The companyÂ’s therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Dermira, Inc., a biopharmaceutical company, engages in identifying, developing, and commercializing therapies to enhance the lives of patients with dermatologic diseases primarily in the United States. The companyÂ’s late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne. It has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.